Paraza Pharma, a Canada based, fully integrated drug discovery organisation, announced on Monday that it has named Edward W (Ted) Marple, AB (Harvard), MBA (Virginia) as its new executive vice-president, Development.
Marple has over 20 years of experience as a senior executive with wide skill sets across clinical development, IP protection, manufacturing, operations, company and product strategy, finance, and commercial partnering/development in the biotechnology and pharmaceutical industry.
Arshad Siddiqui, Ph.D., Paraza founder and CEO, said, 'We are excited to have Ted join Paraza's senior leadership team as we continue to expand our capabilities to better serve our client-partners. Ted's extensive business and commercial expertise will be invaluable to Paraza as we continue to partner with biotechnology and pharmaceutical companies to accelerate research, development and access to new and better treatments for patients.'
Inify Laboratories expands to UK, enters gastrointestinal diagnostics
Eli Lilly's Kisunla gains UK marketing authorisation for alzheimer's treatment
TC BioPharm agrees research planning collaboration to develop Monkeypox treatment
Grifols partners with BARDA to develop treatment for sulfur mustard eye injury
Swedish AI Medical Technologies to begin trial for AI melanoma diagnostic tool
Adcentrx Therapeutics' ADRX-0405 IND application approved by US FDA
HELP Therapeutics' HiCM-188 IND application receives US FDA approval
Trevi Therapeutics finishes enrollment in RCC Phase 2a trial
REGENXBIO reveals positive data for ABBV-RGX-314 in bilateral wet AMD